natgillin/translations-raw huggingface dataset:
Similar findings were reported in rats, and in dogs at 116 mg/m2. 
O podobnih učinkih so poročali pri podganah in psih pri odmerku 116 mg/m2.
Pixuvri must be administered by physicians who are familiar with the use of antineoplastic agents and have the facilities for regular monitoring of clinical, haematological, and biochemical parameters during and after treatment (see section 6.6). 
Zdravilo Pixuvri morajo dajati zdravniki, ki so seznanjeni z uporabo antineoplastičnih zdravil ter ki imajo na razpolago pogoje za redno spremljanje kliničnih, hematoloških in biokemijskih parametrov med zdravljenjem in po njem (glejte poglavje 6.6).
If extravasation occurs the administration should be stopped immediately and restarted in another vein. 
Če se pojavi ekstravazacija, je treba takoj prekiniti dajanje zdravila in začeti infundiranje v drugo veno.
Table 4 Summary of response per independent assessment panel (ITT population) End-of-Treatment 
Tabela 4 Povzetek odzivov po neodvisni skupini za oceno (populacija, ki so jo nameravali zdraviti) konec zdravljenja konec študije
Pixuvri must not be given to pregnant women as it may cause harm to unborn babies. 
Zdravila Pixuvri se ne sme dajati nosečnicam, saj lahko škodi nerojenim otrokom.
No long-term animal studies have been performed to establish the carcinogenic potential of Pixuvri. 
Dolgotrajnih študij na živalih, s katerimi bi lahko ugotovili kancerogeni potencial zdravila Pixuvri, niso izvedli.
The amount of Pixuvri in milligrams that is to be administered to a patient should be determined on the basis of the patient's body surface area (BSA). 
Količino zdravila Pixuvri v miligramih, ki bo dana bolniku, je treba določiti na podlagi bolnikove telesne površine (BSA).
No specific dose adjustment is required in elderly patients (aged ≥ 65 years). 
Starejši Pri starejših bolnikih (starih ≥ 65 let) posebno prilagajanje odmerka ni potrebno.
If Pixuvri (lyophilised powder or reconstituted liquid solution) contacts the skin, wash the skin immediately and flush the membranes thoroughly with water. 
Če zdravilo Pixuvri (liofilizirani prašek ali rekonstituirana raztopina) pride v stik s kožo, jo takoj operite in temeljito izperite sluznice z vodo.
Frequency Undesirable effect 
Pogostnost Neželeni učinek
Patient demographics and baseline disease characteristics were well balanced between the treatment groups, and no statistically significant differences were noted. 
V obeh skupinah so bile demografija bolnikov in izhodiščne značilnosti bolezni uravnovešene ter med njima niso opazili nobenih statistično pomembnih razlik.
Tumour response was assessed by a blinded independent central review panel according to the international workshop to standardise response criteria for NHL. 
Odziv tumorja je ocenila slepa neodvisna osrednja skupina za ocenjevanje skladno z mednarodno delavnico za standardizacijo kriterijev odziva za ne-Hodgkinov limfom.
Modification 
Sprememba
The amounts (dose) of Pixuvri that will be given to you will depend on your body surface area in square meters (m2). 
Količina (odmerek) zdravila Pixuvri, ki vam jo bodo dali, je odvisna od površine vašega telesa v kvadratnih metrih (m2).
This applies to women who can become pregnant and men receiving Pixuvri who may be able to father a child. 
To velja za ženske v rodni dobi ter moške, ki prejemajo zdravilo Pixuvri in bi lahko spočeli otroka.
In the study PIX 301, decreased ejection fraction occurred in 13 patients (19.1%) in the Pixuvri group. 
V študiji PIX 301 je bil iztisni delež manjši pri 13 bolnikih (19,1 %) v skupini, ki je prejemala zdravilo Pixuvri.
If overdose occurs, supportive management is recommended. 
V primeru prevelikega odmerjanja se priporoča podporno zdravljenje.
Contains sodium, see leaflet for further information. 
Vsebuje natrij, za dodatne informacije glejte navodilo za uporabo.
If you will be exposed to sunlight, you should wear sunprotective clothing and use sunscreen that strongly absorbs UV-A. 
Če boste izpostavljeni sončni svetlobi, morate nositi oblačila za zaščito pred soncem in uporabljati kremo za sončenje, ki močno absorbira žarke UV-A.
There is a possibility that your heart pumping function could decrease as a result of the treatment or you might even develop a serious condition called heart failure, especially if your heart function was already compromised at the beginning of the treatment with Pixuvri. 
Obstaja možnost, da se črpanje srca zaradi zdravljenja poslabša ali pa da se pojavi resna bolezen, imenovana srčno popuščanje, zlasti če je bilo delovanje vašega srca oslabljeno že ob začetku zdravljenja z zdravilom Pixuvri.
Pixuvri does not contain anything to prevent the growth of bacteria and it is therefore recommended that it be used immediately after reconstitution. 
Zdravilo Pixuvri ne vsebuje ničesar, kar preprečuje rast bakterij, zato ga je priporočljivo uporabiti takoj po rekonstituciji.
There are no data from the use of pixantrone in pregnant women. 
Podatkov o uporabi piksantrona pri nosečnicah ni.
Your doctor will carry out some tests before you are given Pixuvri. 
Prav tako bo zdravnik opravil nekatere preiskave, preden vam bodo dali zdravilo Pixuvri.
Patients with poor performance status 
Bolniki s slabo oceno zmogljivosti
In vitro studies with the most common human cytochrome P450 isoforms (including CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) have shown a possible mixed-type inhibition of CYP1A2 and CYP2C8 that may be of clinical relevance. 
Študije in vitro z najpogostejšimi izoformami človeškega citokroma P450 (vključno s CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 in 3A4) so pokazale morebitno zaviranje mešanega tipa CYP1A2 in CYP2C8, ki bi lahko bilo klinično pomembno.
Table 1 and Table 2 are recommended as guides to dosage adjustments for days 8 and 15 of the 28- day cycles. 
Tabela 1 in tabela 2 sta priporočeni kot smernici za prilagoditev odmerka 8. in 15. dan 28-dnevnih ciklov.
Average exposures as single agent accounted for: 
Povprečne izpostavljenosti pri uporabi kot samostojno zdravilo so znašale:
Most patients had received prior doxorubicin or equivalent at dose of up to 450 mg/m². 
Večina bolnikov je predhodno prejela doksorubicin ali ekvivalentno zdravilo v odmerku do 450 mg/m2.
The final concentration of pixantrone in the infusion bag should be less than 580 microgram /ml based upon input of reconstituted medicinal product. 
Končna koncentracija piksantrona v vrečki za infundiranje mora biti manjša od 580 mikrogramov/ml na podlagi količine uporabljenega rekonstituiranega zdravila.
Pixuvri is an anticancer medicinal product that is harmful to cells; caution should be exercised in handling. 
Zdravilo Pixuvri je zdravilo proti raku, ki je škodljivo za celice; pri ravnanju z njim morate biti previdni.
The safety and efficacy of Pixuvri in children aged < 18 years has not yet been established. 
Varnost in učinkovitost zdravila Pixuvri pri otrocih, starih < 18 let, še nista bili dokazani.
Pixantrone dimaleate up to 27 mg/kg given twice a week for 4 weeks did not induce any cardiotoxic effects, while mitoxantrone, as expected, was cardiotoxic at all tested doses (0.6, 1.6, and 1.5 mg/kg). 
tedne dajali v odmerku do 27 mg/kg dvakrat na teden, ni povzročil kardiotoksičnih učinkov, medtem ko je bil mitoksantron pričakovano kardiotoksičen pri vseh preizkušenih odmerkih (0,6, 1,6 in 1,5 mg/kg).
Any grade 3 or 4 NYHA* cardiovascular toxicity or persistent LVEF** decline 
Katera koli kardiovaskularna toksičnost 3. ali 4. stopnje po NYHA* ali vztrajajoče zmanjševanje LVEF**
Whilst the effect on fertility has not been ascertained, a precaution will be to advise male patients to use contraceptive methods (preferably barrier) during treatment and for a period of 6 months post-treatment to allow new sperm to mature. 
Čeprav učinka za plodnost niso ocenili, je treba moškim bolnikom kot previdnostni ukrep svetovati, naj med zdravljenjem in 6 mesecev po njem uporabljajo kontracepcijsko metodo (po možnosti barierno), da dozori nova sperma.
Equipment such as vials, needles and syringes used for Pixuvri administration should be handled as toxic waste. 
Opremo, kot so viale, igle in brizge, ki so bile uporabljene za dajanje zdravila Pixuvri, je treba obravnavati kot toksične odpadke.
However, in vitro, conversion of pixantrone into the acetylated metabolites by either NAT1 or NAT2 was very limited. 
Vendar je bila konverzija piksantrona v acetilirane presnovke z NAT1 ali NAT2 in vitro zelo omejena.
Dark blue lyophilised powder. 
Temno moder liofiliziran prašek.
Pixuvri was mutagenic in the Ames test, increased the number of chromosomal aberrations in human lymphocytes, and increased the frequency of micronuclei in vivo. 
Zdravilo Pixuvri je bilo mutageno pri Amesovem testu, povečalo je število kromosomskih aberacij v človeških limfocitih in povečalo pogostnost mikronukleusov in vivo.
It is used for patients whose cancer does not respond or has returned after they have received other chemotherapy treatments. 
Uporablja se pri bolnikih, pri katerih se rak ne odziva ali se je ponovil po drugih kemoterapijah.
The terminal half-life ranged from 14.5 to 44.8 hr with a mean of 23.3 ± 8.0 (n=14, CV=34%) and a median of 21.2 hr. Due to the limited contribution of renal clearance, plasma clearance is mainly non-renal. 
Končni razpolovni čas je bil od 14,5 do 44,8 h, s povprečno vrednostjo 23,3 ± 8,0 (n = 14, koeficient variacije = 34 %) in mediano 21,2 h. Zaradi omejenega prispevka očistka skozi ledvice, je očistek iz plazme predvsem neledvičen.
Pixuvri caused maternal and foetal toxicity in rats and rabbits, even at a dose as low as 1.8 mg/kg given on days 9-11 of pregnancy, higher doses resulting in abortions and total embryo resorption. 
Zdravilo Pixuvri je povzročilo toksičnost za mater in plod pri podganah in kuncih, tudi pri tako majhnih odmerkih, kot je 1,8 mg/kg, ki so jih dajali od 9. do 11. dneva brejosti, višji odmerki pa so povzročali abortuse in popolno resorpcijo ploda.
No drug interactions have been reported in human subjects and no drug-drug interaction studies in humans have been performed. 
Pri človeku niso poročali o medsebojnem delovanju z drugimi zdravili in študij medsebojnega delovanja z drugimi zdravili pri človeku niso izvedli.
There is currently no information on the safety and efficacy of patients with poor performance status (ECOG > 2). 
Informacij o varnosti in učinkovitosti pri bolnikih s slabo oceno zmogljivosti (ocena po lestvici ECOG > 2) trenutno ni na voljo.
Distribution Pixuvri has a large volume of distribution of 25.8 l and is approximately 50% bound to plasma proteins. 
Zdravilo Pixuvri ima velik volumen porazdelitve, 25,8 l, približno 50 % pa je vezano na beljakovine v plazmi.
Following intravenous administration, plasma concentrations of pixantrone reached the maximal concentration at the end of infusion and then declined poly-exponentially. 
Po intravenskem dajanju je koncentracija piksantrona v plazmi dosegla največjo vrednost ob koncu infundiranja, nato pa se je polieksponentno manjšala.
Genotoxicity studies confirmed the potential for clastogenic effects in mammalian cells in vitro and in vivo. 
Študije genotoksičnosti so potrdile potencial za povzročanje klastogenih učinkov v celicah sesalcev in vitro in in vivo.
Dose modification guidelines 
Smernice za spreminjanje odmerka
Patients with neutropenia are more susceptible to infections, although, in the clinical studies there was no increased incidence of atypical, difficult-to-treat infections, such as systemic mycotic infections or infections with opportunistic organisms such as Pneumocystis jiroveci. 
Bolniki z nevtropenijo so bolj dovzetni za okužbe, vendar se v kliničnih študijah pojavnost atipičnih okužb, ki se težko zdravijo, kot so sistemske glivične okužbe ali okužbe z oportunističnimi organizmi, kot je Pneumocystis jiroveci, ni povečala.
In dogs, tachycardia and electrocardiography (ECG) changes occurred immediately after treatment. 
Pri psih so se takoj po dajanju pojavile tahikardija in spremembe pri elektrokardiogramu (EKG).
The incidence of severe infections was low and opportunistic infections associated with immunocompromise were not seen. 
Incidenca hudih okužb je bila majhna, oportunističnih okužb, povezanih z oslabljeno imunostjo, pa niso opazili.
In the clinical trial program, there has been one report of overdose with Pixuvri with no reported concomitant adverse events. 
Iz programa kliničnega preskušanja je bilo eno poročilo o prevelikem odmerjanju zdravila Pixuvri brez poročanih sočasnih neželenih dogodkov.
Pixuvri should not be administered to patients with an active, severe infection or in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose them to serious infection. 
Zdravila Pixuvri se ne sme dajati bolnikom z aktivnimi hudimi okužbami, bolnikom s ponavljajočimi se ali kroničnimi okužbami v anamnezi ali bolnikom z obstoječimi boleznimi, zaradi katerih bi lahko bili dodatno dovzetni za resne okužbe.
In-use storage conditions 
Pogoji shranjevanja med uporabo
Minimal cardiotoxicity of Pixuvri was also demonstrated with repeat treatment cycles at the same doses. 
Minimalno kardiotoksičnost zdravila Pixuvri pri istih odmerkih so pokazali tudi pri ponavljajočih se ciklih zdravljenja.
Pixuvri Dose (mg/m2) Number of patients 
Odmerek zdravila Pixuvri (mg/m2)
Pixantrone may induce hyperuricaemia as a consequence of the extensive purine catabolism that accompanies drug-induced rapid lysis of neoplastic cells (tumour lysis syndrome) and can lead to electrolyte imbalances, which can result in kidney damage. 
Piksantron lahko sproži hiperurikemijo kot posledico obsežnega katabolizma purinov, ki spremlja hitro lizo neoplastičnih celic zaradi zdravila (sindrom lize tumorja), zaradi katerega se lahko pojavi neravnovesje elektrolitov, ki lahko povzroči okvare ledvic.
Males showed, however, slightly higher exposure than females. 
Pri samcih je bila izpostavitev vendar nekoliko večja kot pri samicah.
For the study overall, patient median age was 59, 61% were male, 64% were Caucasian, 76% had Ann Arbor stage III/IV disease at baseline, 74% had a baseline 
V celotni študiji je bila mediana starosti bolnikov 59 let, 61 % bolnikov je bilo moških, 64 % bolnikov je bilo belcev, 76 % bolnikov je imelo ob izhodišču III./IV.
In dogs, the heart was not affected by treatment, as no ECG changes were seen at different treatment times, nor heart changes were detected at gross- and histopathology. 
Pri psih zdravljenje ni vplivalo na srce, saj niso opazili nobenih sprememb EKG pri različnih časih zdravljenja ali sprememb na srcu pri anatomski in histološki patologiji.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°C to 8°C. 
Če se ne porabi takoj, je uporabnik odgovoren za čas in pogoje shranjevanja pred uporabo, to pa ne bi smelo trajati dlje kot 24 ur pri 2 °C do 8 °C.
Unlike approved anthracyclines (doxorubicin and others) and anthracenediones (mitoxantrone), pixantrone is only a weak inhibitor of topoisomerase II. 
Za razliko od odobrenih antraciklinov (doksorubicin in drugi) in antracenedionov (mitoksantron) je piksantron le šibki zaviralec topoizomeraze II.
In repeated-dose studies in mice, rats, and dogs, the main findings were myelotoxicity, nephrotoxicity (except dogs), and testicular damage. 
Pri študijah s ponavljajočimi se odmerki na miših, podganah in psih so opazili predvsem mielotoksičnost, nefrotoksičnost (razen pri psih) in poškodbe testisov.
Table 2 Treatment modifications for non-hematologic toxicities 
Tabela 2 Spreminjanje odmerka zaradi nehematološke toksičnosti
In the EU recommended dose refers to the base of the active substance (pixantrone). 
V EU se priporočeni odmerek nanaša na zdravilno učinkovino (piksantron).
Pixuvri has been shown to cause phototoxic effects on 3T3 cells in vitro. 
Pokazali so, da zdravilo Pixuvri povzroča fototoksične učinke pri celicah 3T3 in vitro.
In addition, caution should be taken when pixantrone is continuously co-administered with efflux transport inducers such as rifampicin, carbamazepin and glucocorticoids, as pixantrone excretion might be increased with a consequent decrease of systemic exposure. 
Poleg tega je pozornost potrebna, kadar se piksantron neprekinjeno sočasno uporablja z induktorji efluksnega transporta, kot so rifampicin, karbamazepin in glukokortikoidi, saj se izločanje piksantrona lahko poveča, kar posledično zmanjša sistemsko izpostavitev.
In dogs, Pixuvri given at 0.5 to 0.9 mg/kg for six cycles did not cause mortality or severe clinical signs, including ECG or body weight changes. 
Pri psih odmerki zdravila Pixuvri od 0,5 do 0,9 mg/kg, ki so jih dajali šest ciklov, niso povzročili smrti ali hudih kliničnih znakov, vključno sprememb EKG ali telesne mase.
The most common toxicity is bone marrow suppression, particularly of the neutrophil lineage. 
Najpogostejša toksičnost je bila supresija kostnega mozga, zlasti linije nevtrofilcev.
Patients on a sodium restricted diet 
Bolniki na dieti z omejenim vnosom natrija
Effects on hepatic or renal function were minimal. 
Učinki na delovanje jeter in ledvic so bili majhni.
After a single intravenous administration of Pixuvri at 29 mg/kg and 38 mg/kg, immediate deaths were seen in mice (114 mg/m2, LD10). 
Po enkratnem intravenskem dajanju zdravila Pixuvri pri odmerkih 29 mg/kg in 38 mg/kg so pri miših opazili takojšnjo smrt (114 mg/m2, LD10).
What Pixuvri is and what it is used for What you need to know before you use Pixuvri How to use Pixuvri 
Kaj je zdravilo Pixuvri in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Pixuvri Kako uporabljati zdravilo Pixuvri
Figure 2 PIX 301 Overall survival-end of study 
Slika 2 Skupno preživetje ob koncu študije PIX 301
Moreover, unlike anthracyclines or anthracenediones, pixantrone directly alkylates DNA forming stable DNA adducts and cross-strand breaks. 
Poleg tega za razliko od antraciklinov ali antracenedionov piksantron neposredno alkilira DNK, pri čemer nastajajo stabilni adukti DNK in prelomi dvojne verig.
There is limited data in patients previously treated with rituximab (38 patients in the Pixuvri arm and 39 patients in the comparator arm). 
Podatki o bolnikih, ki so v preteklosti prejemali rituksimab, so omejeni (38 bolnikov v skupini, ki je prejemal zdravilo Pixuvri, in 39 bolnikov v primerjalni skupini).
This yields a dark blue solution with a pixantrone concentration of 5.8 mg/ml. 
Pri tem nastane temno modra raztopina s koncentracijo piksantrona 5,8 mg/ml.
Catalent UK Packaging Limited Lancaster Way, Wingates Industrial Estate Westhoughton, Bolton, Lancashire BL5 3XX United Kingdom 
Catalent UK Packaging Limited Lancaster Way, Wingates Industrial Estate Westhoughton, Bolton, Lancashire BL5 3XX Velika Britanija
Due to this unique structure, pixantrone produced minimal cardiotoxicity in animal models compared with doxorubicin or mitoxantrone. 
Zaradi svoje edinstvene strukture je piksantron v primerjavi z doksorubicinom ali mitoksantronom povzročil minimalno kardiotoksičnost pri živalskih modelih.
Although the incidence of severe marrow suppression with clinical consequences is relatively low, patients have been treated with Pixuvri were closely monitored by frequent blood counts, particularly for neutropenia. 
Čeprav je pojavnost hude supresije kostnega mozga s kliničnimi posledicami sorazmerno majhna, so pri bolnikih, ki so prejemali zdravilo Pixuvri, pozorno pogosto spremljali krvno sliko, zlasti zaradi nevtropenije.
The occurrence of secondary cancers, including AML and MDS, may occur during or after treatment with Pixuvri. 
Sekundarna rakava obolenja, vključno z AML in MDS, se lahko pojavijo med ali po zdravljenju z zdravilom Pixuvri.
Mantle cell lymphoma patients were not included in the pivotal study. 
Bolniki z limfomom plaščnih celic niso bili vključeni v to ključno študijo.
During treatment with pixantrone, you should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). 
Občutljivost kože na sončno svetlobo Med zdravljenjem s piksantronom morate zmanjšati ali se izogibati izpostavljenosti naravni ali umetni sončni svetlobi (solariji ali zdravljenje z žarki UVA/B).
Catalent UK Packaging Limited Lancaster Way, Wingates Industrial Estate Westhoughton, Bolton Lancashire BL5 3XX United Kingdom 
Catalent UK Packaging Limited Lancaster Way, Wingates Industrial Estate Westhoughton Bolton, Lancashire BL5 3XX Velika Britanija
If cardiac toxicity is demonstrated during treatment, the risk versus benefit of continued therapy with Pixuvri must be evaluated. 
Če se med zdravljenjem pojavi kardiotoksičnost, je treba oceniti tveganja in koristi nadaljevanja zdravljenja z zdravilom Pixuvri.
* NYHA: New York Heart Association ** LVEF: Left Ventricular Ejection Fraction 
** LVEF: Left Ventricular Ejection Fraction (iztisni delež levega prekata).
Any grade 3 or 4 drug-related non cardiac toxicity other than nausea or vomiting 
Katera koli nekardiološka toksičnost 3. ali 4. stopnje, povezana z zdravilom, razen slabosti ali bruhanja
It is not known whether Pixuvri has an effect on the ability to drive a car or use machines. 
Ni znano, ali zdravilo Pixuvri vpliva na sposobnost vožnje in upravljanja strojev.
Pixuvri kills cancer cells by binding to DNA, resulting in cell death. 
Zdravilo Pixuvri ubija rakaste celice tako, da se veže na DNK, kar povzroči smrt teh celic.
Hydration, urine alkalinisation, and prophylaxis with allopurinol or other agents to prevent hyperuricaemia may minimise potential complications of tumour lysis syndrome. 
Hidracija, alkalizacija urina in profilaksa z alopurinolom ali drugimi učinkovinami za preprečevanje hiperurikemije lahko zmanjšajo morebitne zaplete sindroma lize tumorja.
The mixture should be a dark blue solution. 
Zmes mora biti temno modra raztopina.
The BSA should be determined using the institutional standard for BSA calculation and should use a weight measured on day 1 of every cycle. 
Telesno površino je treba določiti skladno z bolnišničnim standardom za njen izračun ter pri tem uporabiti telesno maso, izmerjeno 1. dan vsakega cikla.
Skin discolouration and chromaturia are known related effects of Pixuvri administration due to the colour of the compound (blue). 
Sprememba barve kože in kromaturija sta znana učinka, povezana z uporabo zdravila Pixuvri, zaradi barve spojine (modra).
Hematologic toxicities and complications of neutropenia Hematologic toxicities have been the most frequent toxicity observed but they have, in general, been easily managed with granulocyte-colony stimulating factor (G-CSF) and transfusion support as needed. 
Hematološka toksičnost je bila najpogostejša toksičnost, ki so jo opazili, vendar je bila na splošno lahko obvladljiva z granulocitne kolonije spodbujajoči dejavnikom (G-CSF) in podporo s transfuzijo po potrebi.
Photosensitivity is a potential risk based on in vitro and in vivo non-clinical data. 
Preprečevanje fotosenzitivnostnih reakcij Fotosenzitivnost je možno tveganje, ki temelji na in vitro ter nekliničnih in vivo podatkih.
log rank p-value = 0.251 HR = 0.79 (95% CI 0.53, 1.18) 
P vrednost logrank = 0,251 HR = 0,79 (95-odstotni IZ 0,53, 1,18)
All initial treatment with Pixuvri should be preceded by a careful baseline assessment of blood counts, serum levels of total bilirubin, serum levels of total creatinine, and cardiac function as measured by left ventricular ejection fraction (LVEF). 
Pred vsemi začetnimi zdravljenji z zdravilom Pixuvri je treba opraviti natančno izhodiščno oceno krvne slike, ravni celokupnega bilirubina v serumu, ravni skupnega kreatinina v serumu in srčne funkcije, izmerjene kot iztisni delež levega prekata (LVEF).
Pixuvri with food and drink You do not have to change your diet after treatment with Pixuvri unless instructed by your doctor. 
Zdravilo Pixuvri skupaj s hrano in pijačo Po zdravljenju z zdravilom vam ni treba spremeniti prehrane, razen če vam tega ne naroči zdravnik.
What Pixuvri is and what it is used for 
Kaj je zdravilo Pixuvri in za kaj ga uporabljamo